Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

NCT03411031 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Sponsor no longer providing drug

Conditions

Multiple Myeloma

Interventions

DRUG: Elotuzumab
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]